Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Approved · ActiveModality: prodrug of PTH (1-34) (TransCon; once-daily)
Aliases palopegteriparatide, TransCon PTH
Target PTH receptor (PTH 1-34 prodrug)
Partnerships Teijin Limited (Japan: commercially available since November 2025); VISEN Pharmaceuticals (Greater China); SKYTROFA/VISEN collaboration
Indications
Hypoparathyroidism in adults(Approved)
Status note Approved by FDA August 9, 2024 and authorized by EC November 2023 for treatment of adults with hypoparathyroidism. Commercially available in the U.S. since December 2024; also authorized by other regulatory agencies globally.
SKYTROFA
Approved · ActiveModality: long-acting prodrug of human growth hormone (TransCon; once-weekly)
Aliases lonapegsomatropin-tcgd, TransCon hGH
Target growth hormone receptor
Partnerships VISEN Pharmaceuticals (Greater China; authorized in China January 2026); Teijin Limited (Japan, endocrinology rare diseases)
Indications
Growth hormone deficiency (pediatric patients one year and older)(Approved)
Growth hormone deficiency (adults)(Approved)
Turner syndrome (children)(Stage not disclosed)
Status note FDA approved August 25, 2021 for pediatric GHD and July 25, 2025 for adult GHD; EC marketing authorization January 2022 for children and adolescents 3-18 with GHD. TransCon hGH also in development for children with Turner syndrome and other established daily growth hormone indications.
TransCon CNP
Phase 3 · ActiveModality: prodrug of C-type natriuretic peptide (TransCon)
Aliases navepegritide, TransCon CNP
Target NPR-B (CNP receptor)
Partnerships Teijin Limited (Japan); VISEN Pharmaceuticals (Greater China); combination of TransCon CNP and TransCon hGH under investigation
Indications
Achondroplasia (children)(Phase 3)
Achondroplasia (infants, children, adolescents; alone and in combination with TransCon hGH)(Stage not disclosed)
Hypochondroplasia (children; alone and in combination with TransCon hGH)(Stage not disclosed)
Status note Currently under regulatory review in the United States and European Union for the treatment of children with achondroplasia (NDA pending; company responded to the FDA in September 2025 regarding a Citizen Petition). Also being investigated for achondroplasia in infants, children and adolescents and for hypochondroplasia, alone and in combination with TransCon hGH.
Locally advanced or metastatic solid tumors(Phase 1)
Status note IL-Believe Phase 1/2 trial in locally advanced or metastatic solid tumors, alone or in combination, including a cohort combining with chemotherapy.
Status note Long-acting prodrug of resiquimod. In Q4 2024 the company closed enrollment in the BelieveIT-201 trial and dose expansion cohorts in the transcendIT-101 and IL-Believe trials to prioritize efforts on TransCon IL-2.
Per-asset detail extracted from the 20-F filed 2026-02-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (13 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.